Kinetics of gene expression in murine cutaneous graft-versus-host disease.

straZeneca Research and Development Boston, Waltham, Massachusetts, USA.
American Journal Of Pathology (Impact Factor: 4.6). 07/2004; 164(6):2189-202. DOI: 10.1016/S0002-9440(10)63776-5
Source: PubMed

ABSTRACT The kinetics of gene expression associated with the development of cutaneous graft-versus-host disease (GVHD) were examined in a mouse model of MHC-matched allogeneic hematopoietic stem cell transplantation. Ear skin was obtained from recipient mice with or without GVHD between 7 and 40 days after transplantation for histopathological analysis and gene expression profiling. Gene expression patterns were consistent with early infiltration and activation of CD8(+) T and mast cells, followed by CD4(+) T, natural killer, and myeloid cells. The sequential infiltration and activation of effector cells correlated with the histopathological development of cutaneous GVHD and was accompanied by up-regulated expression of many chemokines and their receptors (CXCL-1, -2, -9, and -10; CCL-2, -5, -6, -7, -8, -9, -11, and -19; CCR-1 and CCR-5), adhesion molecules (ICAM-1, CD18, Ly69, PSGL-1, VCAM-1), molecules involved in antigen processing and presentation (TAP1 and TAP2, MHC class I and II, CD80), regulators of apoptosis (granzyme B, caspase 7, Bak1, Bax, and BclII), interferon-inducible genes (STAT1, IRF-1, IIGP, GTPI, IGTP, Ifi202A), stimulators of fibroblast proliferation and matrix synthesis (interleukin-1beta, transforming growth factor-beta1), and markers of keratinocyte proliferation (keratins 5 and 6), and differentiation (small proline-rich proteins 2E and 1B). Many acute-phase proteins were up-regulated early in murine cutaneous GVHD including serum amyloid A2 (SAA2), SAA3, serpins a3g and a3n, secretory leukocyte protease inhibitor, and metallothioneins 1 and 2. The kinetics of gene expression were consistent with the evolution of cutaneous pathology as well as with current models of disease progression during cutaneous GVHD.


Available from: Aleksandra Petrovic, May 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The pathomechanisms underlying the development of cutaneous graft-versus-host disease (GVHD) are incompletely defined. We previously reported that K14-mOVA mice expressing membrane ovalbumin (mOVA), driven by the keratin 14 (K14) promoter, developed GVHD-like mucocutaneous disease and weight loss following transfer of OVA-specific, CD8(+) OT-I T cells. In this study we demonstrate that early in the course of disease, the kinetics of epidermal expression of CXCL9 and CXCL10, IFN-γ inducible chemokines that bind the CXCR3 receptor, coincides with CXCR3 expression by OT-I cells in secondary lymphoid organs. Recruitment of OT-I cells into the skin began by day 5 with progressive accumulation through day 13 post transfer. Transfer of CXCR3-knockout (CXCR3KO) OT-I cells into K14-mOVA mice resulted in strikingly attenuated skin disease. CXCR3KO OT-I cells retained full activation and effector function, but preferentially accumulated in the spleen, in contrast to wild type (WT) OT-I cells that accumulated in skin-draining lymph nodes. Moreover, OT-I cells accounted for a significantly reduced percentage of skin-infiltrating lymphocytes in mice receiving CXCR3KO OT-I cells compared to WT OT-I cells. These results identify CXCR3 as critical to the skin-selective effector T cell recruitment underlying autoreactive GVHD, suggesting CXCR3 as a potential target in the treatment of GVHD and related skin diseases.Journal of Investigative Dermatology accepted article preview online, 3 January 2014. doi:10.1038/jid.2014.2.
    Journal of Investigative Dermatology 01/2014; DOI:10.1038/jid.2014.2 · 6.37 Impact Factor
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Selective targeting of non-T cells, including antigen presenting cells (APCs), is a potential strategy to prevent graft-versus-host-disease (GVHD) but maintain graft-versus-tumor (GVT) effects. Since type I and II interferons signal through STAT1, and contribute to activation of APCs after allogeneic bone marrow transplant (alloBMT), we examined whether absence of STAT1 in donor APCs could prevent GVHD while preserving immune competence. Transplantation of STAT1(-/-) BM prevented GVHD induced by STAT1(+/+) T cells, leading to expansion of B220(+) cells and regulatory T cells. STAT1(-/-) BM also preserved GVT activity and enhanced overall survival of tumor-challenged mice in the setting of GVHD. Furthermore, recipients of allogeneic STAT1(-/-) BM demonstrated increased CD9-Siglec H(hi) plasmacytoid dendritic cells (pDCs), and depletion of pDCs after STAT1(-/-) BM transplantation prevented GVHD resistance. STAT1(-/-) pDCs were found to produce decreased free radicals, IFNα and interleukin (IL)-12 and increased IL-10. Additionally, STAT1(-/-) pDCs isolated after alloBMT showed increased gene expression of S100A8 and S100A9 and transplantation of S100A9(-/-) BM reduced GVHD-free survival. Finally, elevated STAT3 was found in STAT1(-/-) pDCs isolated after alloBMT. We conclude that interfering with interferon signaling in APCs such as pDCs provides a novel approach to regulate the GVHD/GVT axis.
    Blood 07/2014; 124(12). DOI:10.1182/blood-2013-05-500876 · 9.78 Impact Factor